ICL Group is a Dead Sea minerals franchise asking the market to value a specialty food and crop-nutrition equity while the income statement is still being written by bromine and potash prices. The second-quarter beat is real, and it is not subtle. Adjusted EBITDA rose to $448 million, the best operating-income quarter in three years, and every reporting line contributed to sales. The composition of that beat is the entire debate. Industrial Products and Potash did the heavy lifting through price, not through a sudden conversion of the portfolio into high-return food ingredients. Shareholders who treat the print as proof that the specialty pivot has already arrived are reading the wrong line items.
The same quarter that produced that operating-income high also produced the evidence that the specialty story is not yet carrying earnings. Growing Solutions grew sales and lost earnings power as Brazil, about one third of that franchise, stayed soft while nitrogen and sulfur costs rose. Phosphate Solutions grew the top line and barely moved EBITDA because sulfur spot prices jumped even faster than fertilizer benchmarks. Management still guided full-year adjusted EBITDA inside a band whose floor is $1.5 billion. The ceiling of that same band is $1.7 billion. That guide already assumes the company keeps absorbing a raw-material bill that ran about $100 million higher in the quarter, plus more than $40 million of currency drag. Price is doing the work. Mix is not.
Two board-level decisions now sit on top of the cycle. On August 4 the board approved an end-market reorganization that takes effect at the start of next year, carving Nutrition Solutions out of phosphate and folding commodity potash and phosphate fertilizer into a new Essential Minerals segment. The same results cycle launched Elevate, a productivity program aimed at more than $150 million of annual EBITDA help by late 2027. The longer target is more than $350 million by late 2028. Those programs only matter if they outrun the fade already visible in bromine, which peaked above $6,000 per ton in April and has since eased toward $4,500. The reorganization is an attempt to make the specialty P&L visible. Elevate is an attempt to manufacture earnings if prices mean-revert.
The equity last changed hands near $5.5, with an enterprise value near $9.8 billion. That capitalizes trailing EBITDA at roughly 7 times. Book value sits near $4.8 a share, so the market is paying only a thin premium to invested capital. It is not paying a specialty multiple. It is paying a mid-cycle minerals multiple with a concession discount attached, because the Dead Sea grant that feeds both potash and bromine expires in March 2030 and a December draft bill already points to tougher terms. The next several prints have to show whether Elevate plus the food carve-out can change the mix before bromine mean-reverts and before Israel resets the royalty. Until that evidence arrives, the stock is a priced-in cycle plus an unpriced concession.